A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
BAN2401 is an investigational study drug which is being studied in people who have early AD, with mild cognitive (thinking) impairment or mild dementia. People with AD have a build-up of abnormal protein known as amyloid in their brains. This build up may lead to impairment in memory or thinking.
BAN2401 is a monoclonal (single) antibody. Antibodies are proteins produced by the immune system that bind to foreign substances in the body called antigens. BAN2401 binds to amyloid in the brain in patients with AD and has been shown to reduce the amount of this abnormal protein.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience - known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who have early AD.
There have been three studies of BAN2401. About 688 subjects with AD have been treated with BAN2401 so far.
- IRB Number: 1903099114
- Research Study Identifier: TX10586
- Principal Investigator: Jared Brosch, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required